Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Ganoderma lucidum (also known as Reishi or Lingzhi) has been traditionally used in East Asian medicine for a variety of health purposes, including cardiovascular health. In recent years, several scientific studies have investigated its potential antithrombotic (anti-blood clotting) effects. Laboratory and animal studies have found that extracts of Ganoderma lucidum can inhibit platelet aggregation, which is a key factor in the formation of blood clots. The polysaccharides and triterpenoids present in Ganoderma are believed to be responsible for these effects, as they may modulate pathways involved in coagulation and platelet function.

For example, studies published in peer-reviewed journals have demonstrated that Ganoderma extracts can prolong bleeding time and reduce platelet aggregation in rodents. Some in vitro (test tube) studies have shown that specific components, such as ganoderic acids, inhibit platelet activation and thrombus (clot) formation. However, evidence from human clinical trials is limited and mostly preliminary. There are very few well-designed, large-scale human studies directly examining Ganoderma’s effect on blood clot prevention, so its clinical efficacy and safety in this context remain uncertain.

Therefore, while there is some scientific basis and preclinical evidence to support the potential of Ganoderma for the prevention of blood clots, the quality and quantity of clinical evidence are limited. The current evidence rating is 2 out of 5, reflecting early-stage research that is promising but not yet conclusive for clinical use.

More about ganoderma
More about Blood Clots (prevention of)

Other ingredients used for Blood Clots (prevention of)

Other health conditions supported by ganoderma

Products containing ganoderma